science, business and government are needed, says the director of the institute of translational medicinend biotechnology of sechinov university the ministry of health of russia, vadim tarasov, is building systematic work on the formation of such technological chains when... in recent years, the university has built the entire chain of drug creation, from molecular modeling to clinical trials. now, for russian pharma, we are, first of all, a contract platform that allows russian pharma. solve the problems that are needed in r&d, these are tests, this is the development of finished dosage forms, the development of synthesis technology. the next stage is the creation of a line of innovative products. we received a certain loan trust when we were able to work with a number of our partners, a leading russian pharmaceutical company, to create original products. that is, this is already a kind of apogee, when we are trying together to create truly original molecules, an original drug. wonderful. i understand that the risks are quite high, if 20-30 russian good original drugs appear there a year

medicine and biotechnology.g built to form such technological chains, when research and development centers unite together with business to create drugs, because well, we understand, in the world of creating an innovative first-in-class drug, when a new target is discovered, it may cost there two billion and even 2 and a half dollars. in recent years, the university has built the entire chain of creating drugs from molecular modeling. before clinical trials, now we are primarily a contract platform for russian pharmaceuticals, which allows russian pharmaceuticals to solve the problems that are needed in r&d, these are tests, this is the development of finished dosage forms, the development of synthesis technologies. the next stage is the creation of a line of innovative products. we gained a certain amount of credibility when we were able to come out with a number of our partners, these are leading russian pharmaceutical companies, in the creation of original products. that is, this is already a kind of apogee,

, director of the institute of translational medicine and biotechnology at sechinov university of thematic work is being built to form such technological chains, when research centers... unite - together with business to create drugs, because, well, we understand, in the world of creating innovative medicines from the first to class, when a new target was discovered, it could cost 2 billion or even 2.5 dollars. in recent years, the university has built the entire chain of drug development, from molecular modeling to clinical trials. now, for russian pharmaceuticals, we are, first of all, a contract platform that allows russian pharmaceuticals to decide - these are tests, this is the development of finished dosage forms, the development of synthesis technologies. the next stage is the creation of a line of innovative products. we gained a certain amount of credibility when we were able to work with a number of our partners, these are leading russian pharmaceutical companies, in creating original products. that is, this is already a kind of apogee, when we are trying together to create